Opinion|Videos|December 4, 2024
Standard Treatment Options for BCG-Unresponsive NMIBC
Author(s)Katie S. Murray, DO, MS
Key Takeaways
- Intravesical chemotherapy aims to reduce recurrence and progression but may have limited efficacy and potential side effects.
- PD-L1 inhibitors enhance immune response but can cause immune-related adverse events and have variable patient response.
Katie S. Murray, DO, reviews the standard treatment options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), including intravesical chemotherapy, PD-L1 inhibitors, and other immunotherapeutic agents while highlighting the limitations of these therapies, such as incomplete response rates and potential adverse effects.
Advertisement
Episodes in this series
- Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.
- What limitations do these options have?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves first-line Zenflow system for the treatment of BPH
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5
